The Usefulness of Medroxy-Progesterone Acetate for Genital Spotting after the First Injection of GnRH Agonist Treatment for Endometriosis – Pages 3-6

Sung-Tack Oh and Hyun Kyung Ryu

Department of Obstetrics and Gynecology, Chonnam National University Medical School, Gwangju, Korea

DOI: http://dx.doi.org/10.20941/2309-4400.2018.06.2

Abstract: The best treatment for endometriosis remains gonadotropin-releasing hormone (GnRH) agonist. However, most patients complain of genital spotting during the first month after the injection of GnRH agonist, a distressful side effect of treatment with GnRH agonist for endometriosis. Therefore, we investigated the effect of 10mg daily medroxy-progesterone acetate (MPA) for seven (group 1) or 14 days (group 2) for genital spotting.

We observed the discontinuation of genital spotting and compared the days from medication administration to the discontinuation of genital spotting between the two groups.

(1) In all patients, genital spotting stopped 5–7 days after MPA treatment (p < 0.01).

(2) There was no statistically significant difference in the number of days until discontinuation of genital spotting after 10 mg MPA treatment between the two groups (p = nonspecific).

(3) There was no recurrence of genital spotting in either group during six months of GnRH agonist treatment.

Therefore, genital spotting during the first month following the injection of GnRH agonist was effectively managed with seven days of 10mg/day MPA. This proved to be a very useful treatment method for genital spotting during the first month after the injection of GnRH agonist.

Keywords: Endometriosis, Gonadotropin-releasing hormone agonist, Medroxy-progesterone acetate, Genital spotting.